TY - JOUR T1 - Insights into Praziquantel Metabolism and Potential Enantiomeric Cytochrome P450–Mediated Drug-Drug Interaction JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 481 LP - 490 DO - 10.1124/dmd.119.089888 VL - 48 IS - 6 AU - Gloria Vendrell-Navarro AU - Holger Scheible AU - Floriane Lignet AU - Howard Burt AU - Christian Luepfert AU - Andreas Marx AU - Nada Abla AU - Piet Swart AU - Dominique Perrin Y1 - 2020/06/01 UR - http://dmd.aspetjournals.org/content/48/6/481.abstract N2 - The active enantiomer R-Praziquantel (PZQ) shows a clinically lower relative exposure when administered enantiomerically pure compared with a racemic form. We investigated the hypothesis that enantiomer-enantiomer interactions on cytochrome P450 (P450) enzymes could explain this observation and aimed to further deepen the understanding of PZQ metabolism. First, in an in vitro metabolite profiling study, the formation of multiple metabolites per P450, together with an observed interconversion of cis-4'-OH-PZQ to trans-4'-OH-PZQ in human hepatocytes, pointed out the inadequacy of measuring metabolite formation in kinetic studies. Thus, a substrate depletion approach to study PZQ enantiomeric interactions was applied. Second, an abundant CYP3A4 metabolite found in previous studies was structurally characterized. Third, substrate depletion methodologies were applied to determine P450 enzyme kinetics of PZQ and to further estimate enantiomer-enantiomer inhibitory parameters. A competitive inhibition between PZQ enantiomers for CYP2C9, 2C19, 3A4, and 3A5 was revealed. Analyses considering the clearance of only one or both enantiomers provided comparable enantiomer-enantiomer inhibition estimates. To conclude, this paper provides new insights into PZQ metabolic profile to enable a better understanding of enantioselective pharmacokinetics using substrate depletion-based methods.SIGNIFICANCE STATEMENT In this study, enantiomer-enantiomer interactions of praziquantel on cytochrome P450 metabolizing enzymes are investigated via substrate depletion measurement using modeling methods. Together with new insights into the praziquantel metabolism, this work provides a novel data set to understand its pharmacokinetics. ER -